Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Clearbridge Investments LLC

Clearbridge Investments LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,802 shares of the company’s stock after acquiring an additional 28,805 shares during the period. Clearbridge Investments LLC owned about 0.35% of Neurocrine Biosciences worth $44,904,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Balentine LLC lifted its position in shares of Neurocrine Biosciences by 4.0% in the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock worth $305,000 after buying an additional 89 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in Neurocrine Biosciences by 37.1% in the 4th quarter. Coldstream Capital Management Inc. now owns 3,208 shares of the company’s stock valued at $423,000 after purchasing an additional 868 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in Neurocrine Biosciences in the 4th quarter valued at about $634,000. UBS Group AG lifted its position in Neurocrine Biosciences by 6.4% in the 4th quarter. UBS Group AG now owns 143,894 shares of the company’s stock valued at $18,959,000 after purchasing an additional 8,655 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S lifted its position in Neurocrine Biosciences by 162.0% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,702 shares of the company’s stock valued at $488,000 after purchasing an additional 2,289 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent research reports. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Mizuho lifted their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 8th. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. The Goldman Sachs Group raised their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Finally, Guggenheim raised their target price on shares of Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $148.96.

Neurocrine Biosciences Stock Down 0.8 %

NASDAQ NBIX opened at $139.43 on Thursday. The stock has a market capitalization of $14.03 billion, a PE ratio of 38.41 and a beta of 0.28. The company has a 50 day moving average price of $138.63 and a two-hundred day moving average price of $131.64. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. As a group, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.17 EPS for the current year.

Insider Transactions at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 200 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total transaction of $28,000.00. Following the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,050,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Neurocrine Biosciences news, insider Eric Benevich sold 75,000 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $139.38, for a total value of $10,453,500.00. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,683,637.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ingrid Delaet sold 200 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a total transaction of $28,000.00. Following the completion of the sale, the insider now directly owns 7,507 shares in the company, valued at approximately $1,050,980. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,770 shares of company stock worth $25,047,308. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.